{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:20:08Z","timestamp":1790306408196,"version":"4.1.0"},"reference-count":52,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>We report the 2-year end-of-study results from the phase 2 COMBI II clinical trial investigating the combination treatment of ruxolitinib and low-dose pegylated interferon alfa-2a in patients with newly diagnosed polycythemia vera (PV). The primary outcome was safety and key secondary endpoints were efficacy, based on hematologic parameters, quality-of-life measurements, and JAK2V617F variant allele frequency (VAF). We used the 2013 European LeukemiaNet and International Working Group-Myeloproliferative Neoplasms Research remission criteria. The remission criteria included remissions in symptoms, splenomegaly, peripheral blood counts, and bone marrow. We included 25 patients with PV with a median age of 70 years; 5 of those had prior thromboembolic events and 3 had computed tomography\u2013verified splenomegaly. Two patients stopped both study drugs; 1 of these due to progression to post-PV myelofibrosis, the only one with a grade 3 infection. No events of herpes zoster infections were observed. None of the patients discontinued treatment due to psychiatric symptoms. The peripheral blood cell count remission rate was 92% at 24\u00a0months. Using the 2013 European LeukemiaNet and International Working Group-Myeloproliferative Neoplasms Research remission criteria, 14 (56%) achieved remission at 24\u00a0months; 3 (12%) achieved complete remission and 11 (44%) achieved partial remission. The following items from the Myeloproliferative Neoplasm Symptom Total Symptom Score were significantly reduced: abdominal discomfort, night sweats, itching, and bone pain. The median JAK2V617F VAF decreased from 47% (95% confidence interval [CI], 35-59) to 7% (95%\u00a0CI, 3-15), and 60% of patients achieved molecular remission. In conclusion, combination treatment improved cell counts; bone marrow cellularity, and fibrosis; and decreased JAK2V617F VAF; with acceptable toxicity in patients with PV. The trial was registered at www.clinicaltrialsregister.eu as #EudraCT2018-004150-13.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013170","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T11:39:10Z","timestamp":1728992350000},"page":"5416-5425","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera"],"prefix":"10.1182","volume":"8","author":[{"given":"Anders Lindholm","family":"S\u00f8rensen","sequence":"first","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-7826","authenticated-orcid":false,"given":"Vibe","family":"Skov","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Kj\u00e6r","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0264-6388","authenticated-orcid":false,"given":"Mads Emil","family":"Bj\u00f8rn","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0740-0555","authenticated-orcid":false,"given":"Christina Schjellerup","family":"Eickhardt-Dalb\u00f8ge","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2873-5928","authenticated-orcid":false,"given":"Morten Kranker","family":"Larsen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7543-9016","authenticated-orcid":false,"given":"Claus H","family":"Nielsen","sequence":"additional","affiliation":[{"name":"2Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Thomsen","sequence":"additional","affiliation":[{"name":"3Department of Diagnostic Imaging, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4377-3209","authenticated-orcid":false,"given":"Lise Mette","family":"Rahbek Gjerdrum","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-3099","authenticated-orcid":false,"given":"Trine Alma","family":"Knudsen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ellervik","sequence":"additional","affiliation":[{"name":"5Department of Research, Production, and Innovation, Soroe, Denmark"},{"name":"6Department of Pathology, Harvard Medical School, Boston, MA"},{"name":"7Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA"},{"name":"8Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik Malthe","family":"Overgaard","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christen Lykkegaard","family":"Andersen","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3936-8032","authenticated-orcid":false,"given":"Hans","family":"Hasselbalch","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"issue":"9","key":"2024102113052286500_bib1","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-alpha2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"Sorensen","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"2024102113052286500_bib2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/leu.2015.326","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone","volume":"30","author":"Kiladjian","year":"2016","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2024102113052286500_bib3","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood-2022-156445","article-title":"Quality of life and symptom burden of patients with MPN during treatment with hydroxyurea or pegylated interferon-alpha2: results from a randomized controlled trial","volume":"140","author":"Knudsen","year":"2022","journal-title":"Blood"},{"key":"2024102113052286500_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.leukres.2017.01.006","article-title":"Pegylated interferon alpha-2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial","volume":"54","author":"Gowin","year":"2017","journal-title":"Leuk Res"},{"issue":"4","key":"2024102113052286500_bib5","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83\u00a0month follow-up of an open-label, phase 2 trial","volume":"4","author":"Masarova","year":"2017","journal-title":"Lancet Haematol"},{"issue":"32","key":"2024102113052286500_bib6","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024102113052286500_bib7","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","article-title":"Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment","volume":"37","author":"Gisslinger","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2024102113052286500_bib8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"2024102113052286500_bib9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2024102113052286500_bib10","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2024102113052286500_bib11","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1097\/HS9.0000000000000645","article-title":"New perspectives of interferon-alpha2 and inflammation in treating Philadelphia-negative chronic myeloproliferative neoplasms","volume":"5","author":"Hasselbalch","year":"2021","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2024102113052286500_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-141223","article-title":"Interferon-alpha (IFN) therapy discontinuation is feasible in myeloproliferative neoplasm (MPN) patients with complete hematological remission","volume":"136","author":"Daltro De Oliveira","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2024102113052286500_bib13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/10428194.2015.1049171","article-title":"Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera","volume":"57","author":"Utke Rank","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2024102113052286500_bib14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/17474086.2017.1284583","article-title":"Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib","volume":"10","author":"Bjorn","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2024102113052286500_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"issue":"33","key":"2024102113052286500_bib16","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024102113052286500_bib17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.leu.2404861","article-title":"Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow","volume":"22","author":"Larsen","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"2024102113052286500_bib18","doi-asserted-by":"crossref","first-page":"e0165336","DOI":"10.1371\/journal.pone.0165336","article-title":"Differential dynamics of CALR mutant allele burden in myeloproliferative neoplasms during interferon alfa treatment","volume":"11","author":"Kjaer","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"2024102113052286500_bib19","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2024102113052286500_bib20","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2024102113052286500_bib21","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3324\/haematol.2011.061390","article-title":"Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients","volume":"97","author":"Gowin","year":"2012","journal-title":"Haematologica"},{"issue":"8","key":"2024102113052286500_bib22","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2024102113052286500_bib23","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.12459","article-title":"Efficacy and safety of pegylated-interferon alpha-2a in myelofibrosis: a study by the FIM and GEM French Cooperative Groups","volume":"162","author":"Ianotto","year":"2013","journal-title":"Br J Haematol"},{"issue":"11","key":"2024102113052286500_bib24","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/cncr.21900","article-title":"A\u00a0phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life","volume":"106","author":"Samuelsson","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"2024102113052286500_bib25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cncr.28441","article-title":"A\u00a0phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea","volume":"120","author":"Verstovsek","year":"2014","journal-title":"Cancer"},{"issue":"1","key":"2024102113052286500_bib26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/hon.2429","article-title":"Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: results from an independent study","volume":"36","author":"Palandri","year":"2018","journal-title":"Hematol Oncol"},{"issue":"9","key":"2024102113052286500_bib27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024102113052286500_bib28","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"2024102113052286500_bib29","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","article-title":"Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy","volume":"132","author":"Porpaczy","year":"2018","journal-title":"Blood"},{"key":"2024102113052286500_bib30","doi-asserted-by":"crossref","first-page":"106313","DOI":"10.1016\/j.leukres.2020.106313","article-title":"Risk of B-cell lymphoma in MPN patients treated with JAK1\/2 inhibitors: contradictory results?","volume":"90","author":"Costanza","year":"2020","journal-title":"Leuk Res"},{"issue":"5","key":"2024102113052286500_bib31","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1212\/01.wnl.0000233889.07772.76","article-title":"Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV","volume":"67","author":"Briani","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"2024102113052286500_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-023-01471-z","article-title":"Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety","volume":"16","author":"Verstovsek","year":"2023","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2024102113052286500_bib33","doi-asserted-by":"crossref","first-page":"19159","DOI":"10.1038\/s41598-021-98565-w","article-title":"Prevalence of peripheral neuropathy defined by monofilament insensitivity in middle-aged and older adults in two US cohorts","volume":"11","author":"Hicks","year":"2021","journal-title":"Sci Rep"},{"issue":"suppl 1","key":"2024102113052286500_bib34","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2018-99-111929","article-title":"Impact on MPN symptoms and quality of life of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia: results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 global phase III trial","volume":"132","author":"Mesa","year":"2018","journal-title":"Blood"},{"key":"2024102113052286500_bib35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00277-023-05577-9","article-title":"Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes","volume":"103","author":"Barbui","year":"2024","journal-title":"Ann Hematol"},{"issue":"1","key":"2024102113052286500_bib36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024102113052286500_bib37","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larran","year":"2012","journal-title":"Blood"},{"issue":"13","key":"2024102113052286500_bib38","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"issue":"16","key":"2024102113052286500_bib39","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2020008109","article-title":"The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms","volume":"137","author":"Hasselbalch","year":"2021","journal-title":"Blood"},{"issue":"14","key":"2024102113052286500_bib40","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/cncr.30679","article-title":"The effect of initial molecular profile on response to recombinant interferon-alpha (rIFNalpha) treatment in early myelofibrosis","volume":"123","author":"Silver","year":"2017","journal-title":"Cancer"},{"key":"2024102113052286500_bib41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40164-017-0090-5","article-title":"Histomorphological responses after therapy with pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)","volume":"6","author":"Masarova","year":"2017","journal-title":"Exp Hematol Oncol"},{"issue":"24","key":"2024102113052286500_bib42","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","article-title":"Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report","volume":"117","author":"Silver","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2024102113052286500_bib43","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.leukres.2013.06.012","article-title":"Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha","volume":"37","author":"Stauffer Larsen","year":"2013","journal-title":"Leuk Res"},{"issue":"7","key":"2024102113052286500_bib44","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00277-017-2994-x","article-title":"Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study","volume":"96","author":"Vannucchi","year":"2017","journal-title":"Ann Hematol"},{"issue":"1","key":"2024102113052286500_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620710394474","article-title":"JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment","volume":"2","author":"Vannucchi","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"2024102113052286500_bib46","article-title":"(S219) JAK2V617F molecular response correlates with event-free survival in an early polycythemia vera population","author":"Kiladjian","year":"2024","journal-title":"Hemasphere"},{"issue":"15","key":"2024102113052286500_bib47","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2024102113052286500_bib49","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"19","key":"2024102113052286500_bib50","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A\u00a0randomized phase 3 trial of interferon-alpha vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024102113052286500_bib51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","article-title":"Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?","volume":"41","author":"Hasselbalch","year":"2019","journal-title":"Semin Immunopathol"},{"issue":"6","key":"2024102113052286500_bib52","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a","volume":"122","author":"Quintas-Cardama","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2024102113052286500_bib53","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/20\/5416\/2247379\/blooda_adv-2024-013170-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/20\/5416\/2247379\/blooda_adv-2024-013170-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T09:05:45Z","timestamp":1729501545000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/20\/5416\/517472\/Combination-therapy-with-ruxolitinib-and-pegylated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":52,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024,10,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013170","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]}}}